Literature DB >> 15888760

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma.

R Stupp1, N Pavlidis, S Jelic.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15888760     DOI： 10.1093/annonc/mdi834

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  22 in total

1.  A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

Authors:  Alba A Brandes; Antoine F Carpentier; Santosh Kesari; Juan M Sepulveda-Sanchez; Helen R Wheeler; Olivier Chinot; Lawrence Cher; Joachim P Steinbach; David Capper; Pol Specenier; Jordi Rodon; Ann Cleverly; Claire Smith; Ivelina Gueorguieva; Colin Miles; Susan C Guba; Durisala Desaiah; Michael M Lahn; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2016-02-21       Impact factor: 12.300

2.  Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma.

Authors:  Hiroaki Nagashima; Takashi Sasayama; Kazuhiro Tanaka; Katsusuke Kyotani; Naoko Sato; Masahiro Maeyama; Masaaki Kohta; Junichi Sakata; Yusuke Yamamoto; Kohkichi Hosoda; Tomoo Itoh; Ryohei Sasaki; Eiji Kohmura
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

Review 3.  Ion transporters in brain tumors.

Authors:  Damin Cong; Wen Zhu; John S Kuo; Shaoshan Hu; Dandan Sun
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

4.  Prognostic value of plasma d-dimer levels in patients with glioblastoma multiforme - Results from a pilot study.

Authors:  Matthias Hoke; Karin Dieckmann; Renate Koppensteiner; Martin Schillinger; Christine Marosi; Wolfgang Mlekusch
Journal:  Wien Klin Wochenschr       Date:  2011-03-28       Impact factor: 1.704

5.  Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Authors:  Evanthia Galanis; S Keith Anderson; Jackie M Lafky; Joon H Uhm; Caterina Giannini; Shaji K Kumar; Teresa K Kimlinger; Donald W Northfelt; Patrick J Flynn; Kurt A Jaeckle; Timothy J Kaufmann; Jan C Buckner
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

6.  S100B-p53 disengagement by pentamidine promotes apoptosis and inhibits cellular migration via aquaporin-4 and metalloproteinase-2 inhibition in C6 glioma cells.

Authors:  Elena Capoccia; Carla Cirillo; Annalisa Marchetto; Samanta Tiberi; Youssef Sawikr; Marcella Pesce; Alessandra D'Alessandro; Caterina Scuderi; Giovanni Sarnelli; Rosario Cuomo; Luca Steardo; Giuseppe Esposito
Journal:  Oncol Lett       Date:  2015-04-01       Impact factor: 2.967

7.  Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.

Authors:  C Lecointre; L Desrues; J E Joubert; N Perzo; P-O Guichet; V Le Joncour; C Brulé; M Chabbert; R Leduc; L Prézeau; A Laquerrière; F Proust; P Gandolfo; F Morin; H Castel
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

8.  FasL gene knock-down therapy enhances the antiglioma immune response.

Authors:  Timothy Jansen; Betty Tyler; Joseph L Mankowski; Violette Renard Recinos; Gustavo Pradilla; Federico Legnani; John Laterra; Alessandro Olivi
Journal:  Neuro Oncol       Date:  2010-01-29       Impact factor: 12.300

9.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

10.  Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.

Authors:  Pei Yang; Yongzhi Wang; Xiaoxia Peng; Gan You; Wei Zhang; Wei Yan; Zhaoshi Bao; Yinyan Wang; Xiaoguang Qiu; Tao Jiang
Journal:  J Neurooncol       Date:  2013-03-13       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.